STOCK TITAN

Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Sensei Biotherapeutics (Nasdaq: SNSE) announced its participation in Citi's 2024 Global Healthcare Conference. The conference will take place from December 3-5 in Miami, FL. As a clinical stage biotechnology company specializing in next-generation cancer therapeutics, Sensei's management team will be present at this significant healthcare industry event.

Loading...
Loading translation...
Argus Session date unavailable
-2.57% session move Open Argus
Details

News Market Reaction – SNSE

The recorded move for SNSE in the trading session of this news was -2.57%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi’s 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL.

About Sensei Biotherapeutics  
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.

Investor Contact:
Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
mbiega@senseibio.com

Media Contact:
Joyce Allaire
LifeSci Advisors
Jallaire@lifesciadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Sensei Biotherapeutics (SNSE) participating in Citi's 2024 Global Healthcare Conference?

Sensei Biotherapeutics will participate in Citi's 2024 Global Healthcare Conference from December 3-5, 2024, in Miami, FL.

Where will Citi's 2024 Global Healthcare Conference featuring Sensei Biotherapeutics (SNSE) be held?

The conference will be held in Miami, Florida.

What is Sensei Biotherapeutics' (SNSE) main focus as presented at the Citi Healthcare Conference?

Sensei Biotherapeutics is a clinical stage biotechnology company focused on discovering and developing next-generation therapeutics for cancer patients.

Which stock exchange is Sensei Biotherapeutics (SNSE) listed on?

Sensei Biotherapeutics is listed on the Nasdaq stock exchange under the ticker symbol SNSE.

Keep reading